Physician profile
Robert R Ramirez
NPI 1285606996
$1,663.05
in general payments reported to CMS, 2019-2025
22 companies · $560 in 2025
The $560 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $232 · 2021: $325 · 2022: $95.61 · 2023: $26.06 · 2024: $175 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $307.27 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $144.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $125.35 | 2020-2025 | Farxiga |
| Alk-Abello, INC | $121.95 | 2019 | |
| Genentech USA, INC. | $117.86 | 2025 | Xolair |
| Genentech, INC. | $112.25 | 2025 | Xolair |
| Bayer Healthcare Pharmaceuticals INC. | $109.24 | 2021-2025 | |
| Amgen INC. | $103.22 | 2022-2025 | Repatha, Otezla |
| Lilly USA, LLC | $71.68 | 2021-2025 | Mounjaro, Kisunla |
| Sanofi-Aventis U.S. LLC | $61.02 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $37.23 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $32.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $29.80 | 2021 | |
| Esperion Therapeutics, INC. | $26.38 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $26.12 | 2025 | Inspire |
| Carestream Dental, LLC | $21.60 | 2019 | |
| Abbott Laboratories | $19.75 | 2024 | Proclaim |
| Amarin Pharma, INC. | $16.27 | 2019 | |
| Exact Sciences Corporation | $13.87 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $13.34 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.